U.S. markets close in 2 hours 6 minutes

Shionogi & Co., Ltd. (SGIOY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
13.67+0.20 (+1.48%)
As of 1:37PM EDT. Market open.

Shionogi & Co., Ltd.

1-8, Doshomachi 3-chome
Chuo-ku
Osaka 541-0045
Japan
81 6 6202 2161
http://www.shionogi.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees5,485

Key Executives

NameTitlePayExercisedYear Born
Dr. Isao TeshirogiCEO, Pres & Representative Director1.75MN/A1959
Ms. Takuko Yamada-SawadaExec. VP, Sr. VP of Integrated Disease Care Division & Director877.37kN/A1955
Mr. Noriyuki KishidaSr. Exec. Officer & Sr. VP of Admin. DivisionN/AN/AN/A
Mr. Yoshimasa KyokawaVP of Corp. Communications & Sec. OfficeN/AN/AN/A
Yoshihiro FuruyaVP of Gen. Marketing and Compliance Officer of Corp. GXP Compliance OfficeN/AN/AN/A
Mr. Kohji Hanasaki Ph.D.Sr. Exec. Officer & Sr. VP of Corp. Strategy DivisionN/AN/AN/A
Dr. John A. KellerSr. Exec. Officer & Sr. VP of Global Bus. DivisionN/AN/A1965
Mr. Takeshi ShiotaSVP of Pharmaceutical Research Div, GM of Innovative Drug Discovery Research Labs & Corp OfficerN/AN/AN/A
Mr. Kazuhiro HatanakaSr. Exec. Officer of Pharmaceutical Commercial DivisionN/AN/AN/A
Akira Kato Ph.D.Corp. Officer & GM of Bus. Devel. DepartmentN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with InveniAI, LLC.; Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Corporate Governance

Shionogi & Co., Ltd.’s ISS Governance QualityScore as of July 1, 2021 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.